LENSAR Inc
LNSR
$5.80 2.84%
Exchange NASDAQ Sector Healthcare Industry Medical Devices
Q4 2024
Reported
Published: Apr 30, 2025

Data: Financial Modeling Prep

Company Status Snapshot

Fast view of the latest quarter outcome for LNSR

Report Date

Apr 30, 2025

Quarter Q4 2024

Revenue

16.73M

YoY: +38.2%

EPS

-1.61

YoY: -360.0%

Market Move

+2.84%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Gross Margin

42.5%

Net Income

-18.70M

YoY: -376.4%

"LENSAR's performance in 2024 can be summarized in one word, outstanding."

— Nicholas Curtis
LNSR
Company LNSR

Swipe to view all report sections

Executive Summary

LENSAR delivered a standout fourth quarter of 2024, underscoring the momentum behind its ALLY laser cataract system and the strategic shift toward recurring revenue. Q4 2024 revenue rose to $16.7 million, up 38% year over year, supported by 31 ALLY system placements in the quarter (the highest quarterly placement on record) and a materials-driven mix that increasingly emphasizes high-margin, procedure-based revenue. Full-year 2024 revenue growth was 27% year over year, with recurring revenue totaling approximately $10.8 million in Q4 and exceeding $40 million for the year, illustrating a meaningful pivot toward ongoing service and procedural contributions as new systems ramp toward full productivity.

Despite strong operating execution, the GAAP net loss of $18.7 million in Q4 2024 was driven principally by a $17.6 million noncash charge related to the fair value of warrant liabilities, tied to a 155% increase in LNSR’s stock price in 2024. On a non-GAAP basis, the company posted positive adjusted EBITDA of $0.478 million in Q4 2024—the second consecutive quarterly period of positive adjusted EBITDA—highlighting improving operating leverage as the installed base expands. The gross margin was 42% in Q4 (vs. 43% in Q4 2023), with the full-year gross margin at 48%; management expects gross margins to approach 50% in 2025 as the mix shifts toward higher-margin, procedure-based revenue. LNSR ended 2024 with a cash and investments balance of $22.5 million and generated roughly $3.66 million of operating cash flow in the quarter, contributing to a subdued annual cash burn of about $2.1 million for the year. Management reaffirmed a constructive 2025 outlook, projecting revenue growth above 27% for the year and positive adjusted EBITDA for the full year, with quarterly cadence skewed toward the seasonally strongest fourth quarter.

Strategically, LNSR expanded ALLY beyond the United States with EU and Southeast Asia launches and continued to build a global installed base (ALLY >135 systems and total installed base over 385). Importantly, the company reported 75% of 2024 U.S. system placements were with customers new to LENSAR, underscoring demand traction and the potential for durable recurring revenue as new users scale throughput. Management remains focused on expanding in-key markets, advancing multiple operating-room deployments, and maintaining a disciplined expansion of the commercial organization to capture continued share gains in 2025 and beyond.

Key Performance Indicators

Revenue
Increasing
16.73M
QoQ: 23.58% | YoY: 38.22%
Gross Profit
Increasing
7.11M
42.48% margin
QoQ: 13.44% | YoY: 45.78%
Operating Income
Increasing
-1.29M
QoQ: -27.34% | YoY: 56.43%
Net Income
Decreasing
-18.70M
QoQ: -1 145.14% | YoY: -376.36%
EPS
Decreasing
-1.61
QoQ: -1 138.46% | YoY: -360.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 13.43 1.56 +6.3% View
Q1 2025 14.16 -2.32 +33.7% View
Q4 2024 16.73 -1.61 +38.2% View
Q3 2024 13.54 -0.13 +38.2% View
Q2 2024 12.64 -0.79 +5.2% View